Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.

doi:10.1007/s00432-016-2331-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.

Journal of cancer research and clinical oncology - 1 May 2017

Ye Li, Ren Yanling, Zhou Xinping, Mei Chen, Ma Liya, Ye Xingnong, Wei Juying, Xu Weilai, Meng Haitao, Qian Wenbin, Mai Wenyuan, Lou Yinjun, Xu Gaixiang, Qian Jiejing, Lou Yejiang, Luo Yingwan, Xie Lili, Lin Peipei, Hu Chao, Jin Jie, Tong Hongyan

Abstract excerpt

PURPOSE: The aim of this study was to examine whether decitabine priming prior to low-dose chemotherapeutic regimens could improve outcomes in patients with myelodysplastic syndromes-refractory anemia with excess of blasts (MDS-RAEB). METHODS: The current retrospective analysis included all MDS-RAEB patients receiving idarubicin/cytarabine (IA) or aclacinomycin/cytarabine (AA), with or without decitabine priming...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Cytarabine

Share to Decitabine

Share to Dose-Response Relationship, Drug

Share to Drug Administration Schedule

Share to Karyotype

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 28108816
DOI: 10.1007/s00432-016-2331-0
PMCID: PMC5384967

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.PMID 28108816Read ↗

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.Semantic proximity Read ↗

Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen.Semantic proximity Read ↗

[A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].Semantic proximity Read ↗

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.Semantic proximity Read ↗

Elevated serum direct bilirubin is predictive of a poor prognosis for primary myelodysplastic syndrome.Semantic proximity Read ↗

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AMLSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Hematopoietic Stem Cells Undergo Differentiation State Reprogramming to Overcome Venetoclax Sensitivity in Patients with Myelodysplastic SyndromesSemantic proximity Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Novel combinations to improve hematopoiesis in myelodysplastic syndromeSemantic proximity Read ↗

[Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].Semantic proximity Read ↗

Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation blockSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.